Last checked at 5 Jul 2017 07:00
5 July 2017
IXICO plc
("IXICO" or the "Company")
IXICO signs new contract for specialist imaging clinical trial services
Expansion of customer base, and endorsement of IXICO's expertise in providing both PET and MR imaging services in neuroscience clinical trials
IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, today announces that it has signed a new contract for specialist imaging clinical trial services. The contract is for a Phase II clinical trial of patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease (AD). Sponsored by specialist Spanish biotech company Araclon Biotech, a Grifols company, this phase II of the study is designed to establish the dosage regimen for the therapy, as well as confirm the treatment safety and tolerability data obtained in phase I.
Using our TrialTracker™ digital platform, IXICO will collate both PET and MRI scans acquired at specialist imaging centres across Europe. This data will be then analysed using IXICO's patent protected image analysis technology, which has been customised to evaluate patient eligibility, assess target engagement and quantify drug effects in AD patients.
Giulio Cerroni, Chief Executive of IXICO, commented: "We are delighted to be working with Araclon Biotech which continues our success in providing our customers with a solution that spans both PET and MR imaging services. It is a great example of IXICO's growing value to the biopharmaceutical industry and reinforces our confidence in revenue growth this financial year."
Manuel Sarasa, Chief Scientific Officer of Araclon, commented: "It is an important milestone for us to initiate phase II of clinical trials for our Azheimer´s vaccine -ABvac40- after receiving approval from the Spanish Agency of Medicinal Products and Medical Service. We are a little closer to achieving our goal, so it is fundamental for us to incorporate the best-in-class suppliers, such as IXICO, to work together in this amazing project that is also supported by some Spanish institutions such as the Zaragoza University."
For further information please contact:
IXICO plc Giulio Cerroni, Chief Executive Officer Susan Lowther, Chief Financial Officer |
Tel: +44 20 3763 7499 |
|
|
Shore Capital (Nomad and Broker) Bidhi Bhoma / Edward Mansfield/James Wolfe | Tel: +44 20 7408 4090 |
|
|
FTI Consulting Limited (Investor Relations) Simon Conway / Mo Noonan | Tel: +44 20 3727 1000 |
About IXICO
IXICO is the digital technologies company serving neuroscience. Our mission is to transform the pursuit of improving brain health through the application of digital technologies to neuroscience. IXICO's specialist data analytics services are used by the global pharmaceutical industry to select participants for clinical trials, assess the safety and efficacy of new drugs in development and in post marketing surveillance. Our neurological disease focus includes Alzheimer's disease, Huntington's disease, Multiple Sclerosis, Parkinson's disease and our integrated digital platform encompasses the entire drug development lifecycle. It is a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable sponsors to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new companion digital health products targeted at improving patient outcomes.
More information is available on www.IXICO.com
About Araclon Biotech
Araclon Biotech is a Grifols company specializes in researching and developing therapies and diagnostic methods for Alzheimer's disease (AD) and other neurodegenerative diseases. The company, in which Grifols holds a majority stake, focuses on two research areas: the early diagnosis of AD by means of detecting amyloid-beta peptides in the blood, and the treatment of the disease using immunotherapy (vaccines).